Rabies Clinical Trial
Official title:
A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Efficacy of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) and Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
This is a prospective, randomized, double-blind, and single period non-inferiority and safety study conducted at a single study site. Subjects were randomized into the following two groups: Group A: KamRAB (20 IU/kg by weight [bw]) intramuscular (IM), rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM Group B: Human rabies immune globulin (HRIG) Comparator product (20 IU/kg bw) IM, rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM The primary endpoint was a dichotomous (0-1) variable, defined by reaching an anti-rabies immunoglobulin G (IgG) concentration ≥0.5 IU/mL on Day 14. The primary hypothesis was that the proportion of KamRAB + vaccine recipients with anti-rabies concentration ≥0.5 IU/mL on Day 14 would not be less than the corresponding proportion of HRIG Comparator subjects by as much as 0.1. The safety and tolerability of the study treatments was assessed based on: vital signs and physical examination findings, electrocardiogram (ECG), laboratory findings (hematology, clinical chemistry, and urinalysis) and the occurrence of adverse events (AEs) after drug administration ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03961555 -
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
|
Phase 2 | |
| Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
| Active, not recruiting |
NCT05667974 -
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
|
Phase 3 | |
| Completed |
NCT01641315 -
Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
|
N/A | |
| Completed |
NCT02238756 -
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01930357 -
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
|
Phase 2 | |
| Completed |
NCT01680016 -
A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
|
Phase 3 | |
| Completed |
NCT04019444 -
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02729168 -
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
|
N/A | |
| Completed |
NCT02241135 -
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01388985 -
Simplifying the Rabies Pre-exposure Vaccination
|
Phase 3 | |
| Completed |
NCT04829630 -
Immunity Persistence After Abridged Intradermal Rabies PEP
|
N/A | |
| Completed |
NCT03713086 -
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05350735 -
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
|
N/A | |
| Active, not recruiting |
NCT06132789 -
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
|
Phase 1 | |
| Completed |
NCT02281396 -
The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
|
Phase 1 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Completed |
NCT00825305 -
Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
|
Phase 3 | |
| Completed |
NCT05547815 -
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
|
Phase 4 | |
| Completed |
NCT02564471 -
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
|
Phase 4 |